Currently, only 10% of people with lung cancer will survive their disease for 10 years or more, something we urgently need to address. We have been at the heart of progress in lung cancer for over 50 years. TRACERx is our flagship investment which has unveiled new causes of lung cancer, unlocked potential new ways to diagnose and treat it and fostered the lung cancer research community in the UK.
Up to 14% of people with lung cancer in the UK have never smoked. New research funded by us reveals why non-smokers face delays in getting diagnosed with lung cancer
Today, we’ve announced TRACERx EVO, a new programme that builds on the discoveries made in the world’s largest long-term lung study, TRACERx.